In vivo and in vitro preclinical studies have demonstrated that PR function can be blocked by prototypical anti-progestogens known as selective progesterone receptor modulators (SPRMs), mifepristone or onapristone to control breast cancer progression [109,110,111]. Here, PGR is linked to breast cancer.